Zomedica Corp. · OTC:ZOMDF
Zomedica — Virtual Investor Summit Q3 August 2022
39 slides from Zomedica's conference presentation, Aug 18, 2022
Slide 1: “It’s All In The Waves”
WN <> ZOMEDICA “It’s All In The Waves” Larry Heaton Chief Executive Officer ZOM LISTED NYSE AMERICAN 8/18/2022
Slide 2: Forward Looking Statements
Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or
Slide 3: Zomedica Investment Highlights
Zomedica • Animal health market $88.6 Investment Experienced, Large Growing Markets in billion by 2028(1) • Diagnostics to reach $12.6 Highlights Diagnostics & billion by 2026 Focused Therapeutics Management Team Low Cash Burn Cash on Hand $8M 1H22 $187M (6/30/22) Pathway to Profitability Gross Marg
Slide 4: Veteran Management Team with Decades of Experience
Veteran Management Team with Decades of Experience Larry Heaton Ann Cotter Tony Blair Karen DeHaan-Fullerton CEO CFO COO Chief Counsel & Corporate Secretary 35+ Years of 25+ Years of 30+ Years of 20+ Years of Experience Experience Experience Experience Adrian Lock Greg Blair Nicole Westfall VP Gener
Slide 5: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas PulseVet® Shock Wave System Clinically Proven Global Leader TRUFORMA® Reference Lab Accuracy with Point of Care Convenience Expand Equine Indications Drive assay utilization Launch into for use to grow utilization Expand installed small animal Expand assay offerings bas
Slide 6: Diverse Go To Market Strategy
Diverse Go To Market Strategy Field Sales Reps Email Marketing Inside Sales Reps Public Relations Professional Services Veterinarians Custom Marketing and SEO Event and Conference Sales Web and Social Media International Sales Distributers Print and Catalog Ads Unified Multi- Marketing Ecommerce Dir
Slide 7: Substantial Year-Over-Year Revenue Growth
Substantial Year-Over-Year Revenue Growth Diagnostics net revenue (United Stated dollars in thousands) Therapeutics net revenue (United Stated dollars in thousands) $200 $10,000 $175 $9,000 +41% +398% $8,000 $150 $7,000 $125 $6,000 $100 $5,000 $4,000 $7,849 $75 $148 $3,000 $5,552 $50 $2,000 $25 $1,0
Slide 8: Zomedica Commercial Launch Cadence
Zomedica Commercial Launch Cadence 1H21 2H2021 1H2022 2H2022 1H2023 2H2023 TRUFORMATSH/TT4/Cortisol TRUFORMAeACTH TRUFORMAfT4 TRUFORMAGI Assays PulseVetproducts Assisiproducts SMPVetGuardian Revo2 SonoView Revo2 MicroView
Slide 9: Global Sales Footprint
Global Sales Footprint UXR MedEquus Western Drug Distribution Center _(UK, Belgium, Luxembourg, Denmark, Sweden, Norway) Holistic Veterinary Solutions : . a (Canadc) E Companion Consultancy PulseVet Europe (UK) (Switzerland —Consultant) DAME IC VE DISTIC LTD STI MWI Veterinary Supply Co. MaRS) 7 (Tu
Slide 10: Revolutionary reference lab quality immunoassay diagnostics with point of care convenience
Revolutionary reference lab quality immunoassay diagnostics with point of care convenience
Slide 11: Companion Animal Diagnostics – Large Growing Addressable Market
Companion Animal Diagnostics – Large Growing Addressable Market Proof… Veterinarians cite Diagnostics are diagnostics testing increasingly important to practice health as Vet volume growth as a Pharma shifts to online top driver of practice and retail channels.(2) economics (3) 10% JP Morgan estimat
Slide 12: TRUFORMA Seeks to Change this Dynamic for Veterinarians, Patients and Pet Parents
Zomedica believes that existing in-clinic testing platforms do not provide the accuracy and precision necessary for the timely diagnosis and treatment of certain conditions TRUFORMA® Seeks to Change this Dynamic for Veterinarians, Patients and Pet Parents 12
Slide 13: Based on clinically proven Bulk Acoustic Wave (BAW) technology
• Based on clinically proven, highly sensitive Bulk Acoustic Wave (BAW) technology • Developed and commercialized by Qorvo in Telecom & Aerospace industries • FDA emergency use authorization for COVID testing by Qorvo Biotechnologies Disposable Compact Timely and Cartridge Instrument Accurate Preloa
Slide 14: TRUFORMA Assay Development Targets
TRUFORMA® Assay Development Targets Multiple assay targets drive utility for the practitioner. On the Market In Development Potential Opportunities Adrenal & Thyroid Panel for Dogs Expanding into high value Point Becoming a broad-based Point and Cats of Care solutions of Care lab solution Now Availa
Slide 15: Commercialization Imperatives
Commercialization Imperatives • Grow Installed Base • Customer Appreciation Program facilitates growth in installed base by “placing” instruments with no capital required • Drive Utilization • MyZomedica portal provides easy-to-read test results and easy-to-use ordering process • Providing clinical
Slide 16: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas PulseVet® Shock Wave System Clinically Proven Global Leader TRUFORMA® Reference Lab Accuracy with Point of Care Convenience Expand Equine Indications Drive assay utilization Launch into for use to grow utilization Expand installed small animal Expand assay offerings bas
Slide 17: PulseVet Shock Wave Therapy Available for Equine and NOW Small Animal
PulseVet Shock Wave Therapy Available for Equine and NOW Small Animal
Slide 18: PulseVet Overview
PulseVet® Overview Zomedica acquired Pulse Veterinary Technologies LLC on October 1, 2021 • PulseVet shock wave therapy is the global market leader and enjoys wide adoption in equine uses with over 40 clinical applications • Over 1,600 systems actively in use; 75% in North America and 25% in the ROW
Slide 19: Indications Treated
Electrohydraulic Shock Wave Generator - Compression and tensile stresses mechanically stimulate cells (“mechano-transduction”) Indications Treated: Tendon/Ligament/Muscle Healing Bone Fracture/Osteotomy Healing Osteoarthritis – Pain management and disease modifying Chronic Pain - Myofascial pain and
Slide 20: PulseVet – Seeing is Believing!
PulseVet – Seeing is Believing! BEFORE P U L S E V E T T R E AT M E N T QUICK CLINIC VISIT AFTER P U L S E V E T T R E AT M E N T
Slide 21: Equine Growth Drivers
Equine Growth Drivers New • First-time purchases by equine Veterinarians continue to grow. Placements • Additional units for busy practices, second locations, multiple Veterinarians. • Upgrades of discontinued models and devices greater than 5 years old System Upgrades • Current ProPulse model is li
Slide 22: Small Animal Opportunity
Small Animal Opportunity Rapid Growth in Small Animal Unit Sales Passionate Early 60 Levarage Sales Total Adopters 50 Footprint Addressable Existing commercial team Market 40 use generated Multiple clinical studies for canine remains in place US companion animal market by Early Adopters experiencing
Slide 23: PulseVet Market Opportunity
PulseVet® Market Small Animal = 30,000 US accounts Opportunity 25% penetration of Small Animal market: - 7,500 Practices; $225 million in Capital Revenue - $50 million in Annual Consumable Revenue Equine Penetration ~25% of 25% of Small Animal Greenfield 4450 accounts Current Run Rate: $16 million/y
Slide 24: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas PulseVet® Shock Wave System Clinically Proven Global Leader TRUFORMA® Reference Lab Accuracy with Point of Care Convenience Expand Equine Indications Drive assay utilization Launch into for use to grow utilization Expand installed small animal Expand assay offerings bas
Slide 25: Assisi Animal Health
Assisi Animal Health • Asset Acquisition closed July 15, 2022 for $22 million & warrants • Assisi manufactures and markets a line of targeted electromagnetic pulse wave devices for relief of pain and inflammation. • Sells through multiple existing channels new to Zomedica: • Veterinarian practices •
Slide 26: Assisi Product Line – Adding Pet Parents to Pet Care Pathway
Assisi Product Line – Adding Pet Parents to Pet Care Pathway • Assisi Loop® is flagship product • Sold for pain and inflammation from OA and wound healing • 2 sizes: 20cm and 10cm • 150 treatments; then replaced with new device • Assisi Loop Lounge® is fastest growing product • Similar uses to the L
Slide 27: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas PulseVet® Shock Wave System Clinically Proven Global Leader TRUFORMA® Reference Lab Accuracy with Point of Care Convenience Expand Equine Indications Drive assay utilization Launch into for use to grow utilization Expand installed small animal Expand assay offerings bas
Slide 28: Revo2 Acquisition
Revo2 Acquisition An innovative veterinary imaging company MicroView Digital Microscopy • Innovative digital imaging system with best-in-class visualization • First in class automated slide preparation • Improves workflow in the clinic • Reduces slide prep errors – improving diagnostic results • All
Slide 29: Proctored Ultrasound
Proctored Ultrasound • Full control of remote systems • Diagnostic instruction • FNA Instruction and guidance • Tru-Cut biopsy Instruction and guidance • Deep tissue injection Instruction and guidance • Intraarticular injection guidance
Slide 30: Zomedica Critical Focus Areas
Zomedica Critical Focus Areas PulseVet® Shock Wave System Clinically Proven Global Leader TRUFORMA® Reference Lab Quality with Point of Care Convenience Expand Equine Indications Drive assay utilization Launch into for use to grow utilization Expand installed small animal Expand assay offerings base
Slide 31: Zomedica & VetGuardian
Zomedica & VetGuardian • Zomedica invested $1m in a convertible note in Structured Monitoring Products, the makers of VetGuardian. Together Zomedica and SMP will work toward establishing this technology as standard of care. • Zomedica and SMP collaborating on final design, cloud integration with MyZ
Slide 32: How Zero-Touch Works
H o w Z er o -To u c h Wo r k s Continuous Waveform Doppler Radar detects pulse and respiration Video camera and LIDAR sensors detect movement Thermal camera and proprietary algorithms will detect temperature
Slide 33: ~$875M Immediate Market Opportunity
Exotics Facilities I m m e d i a t e ~$875M Market Oppo r tunity $100M for U S C o m p a n i o n A n i m a l C l i n i c s Companion Animal Clinics Equine Ranches Ave rage Gross $350M $7,320 Revenue Per $875M Device Animal Research Average Devices Per Clinic 4 Major Production Centers Farms N u m b
Slide 34: Sniffing out Future Technologies
Sniffing out Future Technologies
Slide 35: Business Development Opportunities
Business Development Opportunities Adding to Strong Product Portfolio Accelerating Balance Sheet • PulseVet shock wave therapy Innovation • $187 million cash position as • VetGuardian wireless • Industry innovation accelerating of 6/30/2022 [less $24 million remote monitoring but commercialization i
Slide 36: Financial Foundation & Performance
Financial Foundation & Performance 2022 Balance Sheet as of 6/30/2022 Second Quarter 2022 Profit & Loss Statement ($ 000's) 3 months 6 months Cash and Cash Equivalents 186,763 Revenue 4,246 7,997 Other Current Assets 10,863 Cost of Revenue 1,210 2,199 Gross Profit 3,036 5,798 Total Current Assets 19
Slide 37: Why Invest In Zomedica?
Why Invest In Zomedica? TRUFORMA® provides revolutionary Increasing revenues and attractive PulseVet® continues to grow equine reference lab accuracy with point of care gross margins provide pathway to business both in the US and internationally convenience. Continued investment in assay profitabili
Slide 38: “It’s All In The Waves”
— Investor Relations Contact: —Kirin Smith, President PCG Advisory Inc 646-823-8656 | ksmith@pcgadvisory.com 8/18/2022 <> ZOMEDICA “It’s All In The Waves” ZOM SKSHAEID) NYSE AMERICAN 38
Slide 39: Appendix - Endnotes
Appendix - Endnotes (1) JP Morgan coverage initiation report on Idexx and Heska, January 2021 (2) JP Morgan AH Industry overview Jan 2021 (3) Credit Suisse Animal Health Industry Primer, June 2021 Pg 16 Grandview Research August 2021 Global Market Insights 2016 pet owner survey conducted by The Huma